Published in Neurol Sci on August 22, 2017
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr (2003) 8.61
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv (2012) 1.76
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler (2005) 1.31
[Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]. Rev Neurol (Paris) (2006) 1.24
Monitoring health related quality of life in adolescents with diabetes: a review of measures. Arch Dis Child (2007) 1.11
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Fatigue and quality of life in pediatric multiple sclerosis. Mult Scler (2009) 0.95
The management of multiple sclerosis in children: a European view. Mult Scler (2010) 0.95
Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology (2006) 0.91
Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Mult Scler (2011) 0.89
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Ther Deliv (2011) 0.86
Factors associated with emotional and behavioral outcomes in adolescents with multiple sclerosis. Mult Scler (2012) 0.85
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci (2009) 0.84
Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol (2009) 0.84
Health-related quality of life is reduced in pediatric multiple sclerosis. Pediatr Neurol (2010) 0.83
The Italian version of the PedsQL in children with rheumatic diseases. Clin Exp Rheumatol (2009) 0.81
Therapy of multiple sclerosis in children and adolescents. Clin Neurol Neurosurg (2010) 0.80
Social cognition in pediatric-onset multiple sclerosis (MS). Mult Scler (2014) 0.80
Treatment adherence and transitioning youth in pediatric multiple sclerosis. Mult Scler Relat Disord (2014) 0.79
Navigating life and loss in pediatric multiple sclerosis. Qual Health Res (2014) 0.79
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opin Drug Deliv (2016) 0.78
Fatigue and depression in children with demyelinating disorders. J Child Neurol (2012) 0.78
Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis. Psychiatry Clin Neurosci (2015) 0.78
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues. Adolesc Health Med Ther (2010) 0.77
Quality of life and cognitive functions in early onset multiple sclerosis. Eur J Paediatr Neurol (2015) 0.77
Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics (2013) 0.77
Quality of Life, Cognition and Mood in Adults with Pediatric Multiple Sclerosis. Can J Neurol Sci (2016) 0.77
Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. Mult Scler Relat Disord (2012) 0.77
Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology (2016) 0.77
Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Qual Life Res (2017) 0.76
Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Mult Scler (2017) 0.76
Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics (2016) 0.76
Multiple sclerosis and related disorders: evolving pathophysiologic insights. Lancet Neurol (2015) 0.76